NO20054312L - HIV-replikasjonsinhiberende pyrimidiner og triaziner - Google Patents
HIV-replikasjonsinhiberende pyrimidiner og triazinerInfo
- Publication number
- NO20054312L NO20054312L NO20054312A NO20054312A NO20054312L NO 20054312 L NO20054312 L NO 20054312L NO 20054312 A NO20054312 A NO 20054312A NO 20054312 A NO20054312 A NO 20054312A NO 20054312 L NO20054312 L NO 20054312L
- Authority
- NO
- Norway
- Prior art keywords
- triazines
- hiv replication
- replication inhibitory
- pyrimidines
- inhibitory pyrimidines
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 150000003918 triazines Chemical class 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03100411 | 2003-02-20 | ||
| US47501203P | 2003-06-02 | 2003-06-02 | |
| PCT/EP2004/050177 WO2004074262A1 (en) | 2003-02-20 | 2004-02-20 | Hiv replication inhibiting pyrimidines and triazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054312D0 NO20054312D0 (no) | 2005-09-19 |
| NO20054312L true NO20054312L (no) | 2005-11-16 |
Family
ID=32910137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054312A NO20054312L (no) | 2003-02-20 | 2005-09-19 | HIV-replikasjonsinhiberende pyrimidiner og triaziner |
| NO20054311A NO20054311L (no) | 2003-02-20 | 2005-09-19 | HIV-repliksjonsinhiberende pyrimidiner og triaziner |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054311A NO20054311L (no) | 2003-02-20 | 2005-09-19 | HIV-repliksjonsinhiberende pyrimidiner og triaziner |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7442705B2 (de) |
| EP (2) | EP1603887B1 (de) |
| JP (2) | JP4586013B2 (de) |
| KR (2) | KR20050094896A (de) |
| CN (2) | CN1751031B (de) |
| AP (1) | AP2005003373A0 (de) |
| AR (2) | AR044499A1 (de) |
| AT (2) | ATE506353T1 (de) |
| AU (2) | AU2004213186B2 (de) |
| BR (2) | BRPI0407741B8 (de) |
| CA (2) | CA2516589C (de) |
| CL (2) | CL2004000306A1 (de) |
| CY (1) | CY1106788T1 (de) |
| DE (2) | DE602004006383T2 (de) |
| DK (1) | DK1597238T3 (de) |
| EA (2) | EA010423B1 (de) |
| ES (1) | ES2287734T3 (de) |
| HR (2) | HRP20050821A2 (de) |
| IL (2) | IL169596A (de) |
| MX (2) | MXPA05008867A (de) |
| MY (1) | MY138308A (de) |
| NO (2) | NO20054312L (de) |
| NZ (2) | NZ542428A (de) |
| PL (2) | PL227295B1 (de) |
| PT (1) | PT1597238E (de) |
| TW (2) | TW200500346A (de) |
| WO (2) | WO2004074261A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| EP2543376A1 (de) | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazin Kinasehemmer |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| SI1814878T1 (sl) | 2004-11-24 | 2012-06-29 | Rigel Pharmaceuticals Inc | Spojine spiro-2,4-pirimidindiamina in njihova uporaba |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| BRPI0610876B8 (pt) | 2005-06-08 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| AU2007341228B2 (en) * | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
| AU2007341227C1 (en) * | 2006-12-29 | 2013-08-29 | Janssen Sciences Ireland Uc | HIV inhibiting 6-substituted pyrimidines |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US7737157B2 (en) * | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
| AU2009290474A1 (en) | 2008-09-11 | 2010-03-18 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| EP2604604A1 (de) | 2009-03-11 | 2013-06-19 | Pfizer Inc | Als Glucokinaseinhibitoren verwendete Benzofuranylderivate |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| WO2012135641A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
| EP2704572B1 (de) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs |
| GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
| GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EP3492462B1 (de) | 2016-07-26 | 2023-08-30 | Shenzhen TargetRx, Inc. | Aminopyrimidinverbindung zur hemmung der proteintyrosinkinaseaktivität |
| CN106749203B (zh) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20221083A1 (es) | 2019-06-17 | 2022-07-05 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| BR9611562A (pt) | 1995-11-23 | 1999-03-02 | Janssen Pharmaceutica Nv | Misturas sólidas de ciclodextrinas preparadas via extrusão sob fusão |
| NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| EA002973B1 (ru) * | 1998-03-27 | 2002-12-26 | Янссен Фармацевтика Н.В. | Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека |
| EP0945447A1 (de) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen |
| SK287270B6 (sk) * | 1998-11-10 | 2010-05-07 | Janssen Pharmaceutica N. V. | Derivát pyrimidínu |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| EP1169038B9 (de) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclische protein-tyrosinkinasehemmer |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| TR200200763T2 (tr) * | 1999-09-24 | 2003-09-22 | Janssen Pharmaceutica N.V. | Antiviral bileşimler |
| MXPA02003436A (es) * | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| AU783981C (en) | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
| AU2002216650A1 (en) * | 2000-10-31 | 2002-05-15 | Lynn Bonham | Triazine derivatives as lpaat-b inhibitors and uses thereof |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| KR100875362B1 (ko) * | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
| AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| EP1518855B1 (de) * | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidincarbonsäureamidderivat |
| HRP20050089B1 (hr) * | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
-
2004
- 2004-02-19 CL CL200400306A patent/CL2004000306A1/es unknown
- 2004-02-19 CL CL200400303A patent/CL2004000303A1/es unknown
- 2004-02-20 EP EP04737251A patent/EP1603887B1/de not_active Expired - Lifetime
- 2004-02-20 ES ES04737252T patent/ES2287734T3/es not_active Expired - Lifetime
- 2004-02-20 EA EA200501326A patent/EA010423B1/ru not_active IP Right Cessation
- 2004-02-20 AU AU2004213186A patent/AU2004213186B2/en not_active Ceased
- 2004-02-20 BR BRPI0407741A patent/BRPI0407741B8/pt not_active IP Right Cessation
- 2004-02-20 MX MXPA05008867A patent/MXPA05008867A/es active IP Right Grant
- 2004-02-20 CN CN2004800043209A patent/CN1751031B/zh not_active Expired - Fee Related
- 2004-02-20 WO PCT/EP2004/050175 patent/WO2004074261A1/en not_active Ceased
- 2004-02-20 AP AP2005003373A patent/AP2005003373A0/xx unknown
- 2004-02-20 CN CNB2004800043162A patent/CN100572364C/zh not_active Expired - Fee Related
- 2004-02-20 HR HR20050821A patent/HRP20050821A2/xx not_active Application Discontinuation
- 2004-02-20 TW TW093104173A patent/TW200500346A/zh unknown
- 2004-02-20 EP EP04737252A patent/EP1597238B1/de not_active Expired - Lifetime
- 2004-02-20 US US10/545,358 patent/US7442705B2/en not_active Expired - Lifetime
- 2004-02-20 DK DK04737252T patent/DK1597238T3/da active
- 2004-02-20 EA EA200501327A patent/EA011256B1/ru not_active IP Right Cessation
- 2004-02-20 AR ARP040100548A patent/AR044499A1/es not_active Application Discontinuation
- 2004-02-20 JP JP2006502041A patent/JP4586013B2/ja not_active Expired - Fee Related
- 2004-02-20 CA CA2516589A patent/CA2516589C/en not_active Expired - Fee Related
- 2004-02-20 WO PCT/EP2004/050177 patent/WO2004074262A1/en not_active Ceased
- 2004-02-20 TW TW093104175A patent/TW200510339A/zh unknown
- 2004-02-20 MX MXPA05008866A patent/MXPA05008866A/es active IP Right Grant
- 2004-02-20 US US10/545,719 patent/US7585870B2/en not_active Expired - Lifetime
- 2004-02-20 CA CA2516699A patent/CA2516699C/en not_active Expired - Fee Related
- 2004-02-20 JP JP2006502042A patent/JP4586014B2/ja not_active Expired - Fee Related
- 2004-02-20 KR KR1020057014231A patent/KR20050094896A/ko not_active Ceased
- 2004-02-20 AT AT04737251T patent/ATE506353T1/de not_active IP Right Cessation
- 2004-02-20 MY MYPI20040575A patent/MY138308A/en unknown
- 2004-02-20 PT PT04737252T patent/PT1597238E/pt unknown
- 2004-02-20 NZ NZ542428A patent/NZ542428A/en unknown
- 2004-02-20 PL PL378136A patent/PL227295B1/pl unknown
- 2004-02-20 KR KR1020057014648A patent/KR20050099994A/ko not_active Ceased
- 2004-02-20 BR BRPI0407732-6A patent/BRPI0407732A/pt not_active Application Discontinuation
- 2004-02-20 DE DE602004006383T patent/DE602004006383T2/de not_active Expired - Lifetime
- 2004-02-20 DE DE602004032321T patent/DE602004032321D1/de not_active Expired - Lifetime
- 2004-02-20 PL PL378064A patent/PL226954B1/pl unknown
- 2004-02-20 AT AT04737252T patent/ATE361915T1/de not_active IP Right Cessation
- 2004-02-20 HR HR20050820A patent/HRP20050820A2/xx not_active Application Discontinuation
- 2004-02-20 AU AU2004213187A patent/AU2004213187B2/en not_active Ceased
- 2004-02-20 AR ARP040100549A patent/AR044500A1/es not_active Application Discontinuation
- 2004-02-20 NZ NZ541601A patent/NZ541601A/en unknown
-
2005
- 2005-07-07 IL IL169596A patent/IL169596A/en active IP Right Grant
- 2005-07-12 IL IL169647A patent/IL169647A/en active IP Right Grant
- 2005-09-19 NO NO20054312A patent/NO20054312L/no not_active Application Discontinuation
- 2005-09-19 NO NO20054311A patent/NO20054311L/no not_active Application Discontinuation
-
2007
- 2007-08-03 CY CY20071101039T patent/CY1106788T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054312L (no) | HIV-replikasjonsinhiberende pyrimidiner og triaziner | |
| NO20060001L (no) | Nye P2X7-reseptorantagonister og deres anvendelse | |
| NO20084257L (no) | Diketopiperazin og piperidin derivater som antivirale midler | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20085373L (no) | P38 inhibitorer, deres fremstilling og anvendelse | |
| NO20062726L (no) | Nye pyridazin-3(2H)-on derivater | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| DK1427708T3 (da) | Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| NO20062677L (no) | Benzyleteraminforbindelser anvendbare som CCR-5-antagonister | |
| NO20090628L (no) | Pyridizinon derivativater | |
| NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
| MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
| NO20064062L (no) | Prodroger av piperazin og substituerte piperidin antivirale midler | |
| DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| PL378107A1 (pl) | 1,2,4-triazyny hamujące HIV | |
| NO20066055L (no) | Pyridinderivater | |
| NO20070655L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft | |
| SE0400284D0 (sv) | Novel compounds | |
| NO20085087L (no) | Nye heterocykliske forbindelser | |
| NO20070681L (no) | 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft | |
| NO20085212L (no) | Nye pyridinanaloger | |
| NO20050088L (no) | Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |